EASO Recommendations for Semaglutide and Tirzepatide in Obesity Management

EASO's 2025 Obesity Treatment Guidelines

The European Association for the Study of Obesity (EASO) has released pivotal guidelines recommending semaglutide and tirzepatide as the first-line pharmacologic therapies for individuals facing obesity and its complications.

Key Outcomes from EASO Recommendations

• Semaglutide and Tirzepatide outperformed other available options in clinical trials, showcasing significant weight loss and complication management.
• The EASO emphasizes a holistic management strategy, prioritizing overall health rather than solely focusing on weight reduction.

Complications and Their Management

Researchers categorized obesity complications into fat mass disease and sick fat disease, guiding tailored therapeutic approaches. For instance:

1. For obstructive sleep apnea, tirzepatide is recommended due to robust trial evidence.
2. In cases of knee osteoarthritis, semaglutide is favored for its pain relief effects.
3. Semaglutide also shows potential for those with cardiovascular disease, underscoring its cardiovascular benefits.

Economic Considerations

The guidelines stress the importance of addressing the economic implications of obesity treatments. The long-term costs of untreated obesity, including adverse health outcomes, must inform health policy and payer decisions.

Adaptability in Treatment

While the EASO's new algorithm provides structured guidance, medical professionals are encouraged to adapt treatment to individual patient needs, factoring in clinical and personal considerations.

While semaglutide and tirzepatide are spotlighted, other medications may be helpful for patients with lower weight loss goals. Continuous updates on the algorithm will incorporate emerging evidence to refine treatment strategies for obesity efficiently.